Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,376.35
(
-0.12%
)
News Focus
News Focus
Post# of 32075
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

TREND1

Send PM Follow Ignore
Followers 414
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

TREND1

Member Level

Re: Triplezerohero post# 23337

Thursday, 05/11/2017 10:42:44 PM

Thursday, May 11, 2017 10:42:44 PM

Post# of 32075
In January 2017, Novo Nordisk announced that Fiasp ® , a faster formulation of insulin aspart, was approved in Europe and Canada.

It is currently undergoing regulatory review in the United States.

The above would compete with AFREZZA.

FROM 10Q

MAIN BOARD http://investorshub.advfn.com/TRADING-3X-TNA-TQQQ-SPXL-RUS-2000-FUTURES-12981/

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent MNKD News
More MNKD News